Vir Biotechnology advances VIR-5500 into expansion trials in prostate cancer

Pharma firms accelerate regional GLP-1 capacity to de-risk supply chains amid geopolitical tensions: GlobalData

At the centre of this shift is Eli Lilly and Company, whose latest investments in China and Japan are helping redefine the next phase of GLP-1 supply strategy

Alexion to showcase broad neurology pipeline at AAN 2026 with 20 presentations

The programme features headline data from pivotal Phase III trials, including PREVAIL in gMG, KOMET in NF1-PN, and CHAMPION-NMOSD, alongside real-world evidence supporting established therapies

AKM and Kyoto University break ground with 2 µm PCSEL laser

Paves the way for next-gen ultra-precise gas sensing

Boehringer Ingelheim & BioNTech launch high-stakes lung cancer combo trial

BioNTech will supply pumitamig, a PD-L1/VEGF-A bispecific antibody co-developed with Bristol Myers Squibb, while Boehringer Ingelheim will act as the regulatory sponsor of a Phase Ib/II study

Thermo Fisher and Singapore’s PRECISE launch major proteomics push in 100,000-person study

The study’s multi-technology design is intended to improve reproducibility, strengthen regulatory-grade evidence generation

GoodRx partners with Eli Lilly to expand access to new oral GLP-1 Foundayo & Zepbound KwikPen

GoodRx at a starting price of $149 per month—aligned with the lowest available discounted cash price at launch. The rollout includes nationwide pharmacy access

India must build its own agile biopharma innovation model: ICMR DG Dr Rajiv Bahl

At India Pharma 2026, Dr Bahl calls for experimentation over imitation as funding rises and translational ecosystem reforms gather pace

CDSCO reforms cut trial approval timelines by over 50%: DCGI Dr Rajeev Raghuvanshi

Outlines 1,500-member internal cadre, digital regulatory system, and faster SEC-led reviews

Gennova CEO Dr Sanjay Singh sees strong innovation momentum for India’s biopharma sector

Veteran biopharma leader stressed that generic medicines must be viewed separately from biologics